Related Experiment Video

Updated: May 22, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

A novel bFGF antagonist peptide inhibits breast cancer cell growth

Quchou Li1, Susu Gao, Yonglin Yu

  • 1Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, Guangdong 510632, PR China.

Molecular Medicine Reports
|May 12, 2012
PubMed

Insights

A novel peptide, P7, effectively inhibits breast cancer cell proliferation by halting cell cycle progression and blocking key signaling pathways. This bFGF-binding peptide shows promise for future breast cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Breast cancer is a leading global cancer in women.
  • Elevated basic fibroblast growth factor (bFGF) is linked to breast cancer progression.
  • A high-affinity bFGF-binding peptide (P7) was previously identified.

Purpose of the Study:

  • To investigate the therapeutic potential of the P7 peptide in breast cancer.
  • To elucidate the mechanisms by which P7 inhibits cancer cell proliferation.

Main Methods:

  • Utilized phage-display technology to identify the bFGF-binding peptide P7.
  • Assessed P7's effect on MDA-MB-231 breast cancer cell proliferation in vitro.
  • Analyzed cell cycle progression, Erk and P38 signaling pathways, and proliferation-associated protein 2G4 expression.

Main Results:

  • P7 peptide significantly inhibited proliferation of bFGF-stimulated breast cancer cells.
  • P7 induced cell cycle arrest at the G0/G1 phase.
  • P7 blocked Erk and P38 cascade activation and upregulated proliferation-associated protein 2G4.

Conclusions:

  • The bFGF-binding peptide P7 demonstrates significant anti-proliferative effects on breast cancer cells.
  • P7's mechanism involves cell cycle arrest and modulation of key signaling pathways.
  • P7 holds potential as a therapeutic agent for breast cancer treatment.
Keywords:
basic fibroblast growth factor antagonist peptidecell proliferationcell cyclemitogen-activated protein kinase pathwayproliferation-associated protein 2G4

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...